Drug Profile
C 6448
Alternative Names: C-6448Latest Information Update: 03 Jul 2006
Price :
$50
*
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 03 Jul 2006 No development reported - Phase-II for Multiple sclerosis in USA (unspecified route)
- 14 Dec 2004 Phase-II clinical trials in Multiple sclerosis in USA (unspecified route)
- 01 Mar 2004 Phase-I clinical trials in Multiple sclerosis in USA (unspecified route)